| Dr Rachel Lynn Delost, DO | |
|
2223 Niles Cortland Rd Se, Warren, OH 44484-3043 | |
| (330) 965-8760 | |
| (330) 469-9706 |
| Full Name | Dr Rachel Lynn Delost |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 2223 Niles Cortland Rd Se, Warren, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659861839 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 34.015757 (Ohio) | Primary |
| Entity Name | Optima Dermatology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831187764 PECOS PAC ID: 3971561648 Enrollment ID: O20041228000548 |
News Archive
Ore Pharmaceuticals Inc. ("Ore") announced today the receipt of a written notice from the Nasdaq Stock Market ("Nasdaq") stating that for the previous 30 consecutive business days, the bid price of Ore's listed securities had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market pursuant to Marketplace Rule 5550(a)(2).
A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.
Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago, IL.
In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.
› Verified 6 days ago
| Entity Name | Apex Dermatology And Skin Surgery Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689973638 PECOS PAC ID: 1052589777 Enrollment ID: O20110725000647 |
News Archive
Ore Pharmaceuticals Inc. ("Ore") announced today the receipt of a written notice from the Nasdaq Stock Market ("Nasdaq") stating that for the previous 30 consecutive business days, the bid price of Ore's listed securities had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market pursuant to Marketplace Rule 5550(a)(2).
A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.
Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago, IL.
In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rachel Lynn Delost, DO 111 New Hampshire Ave Ste 2, Portsmouth, NH 03801-2864 Ph: (802) 909-2053 | Dr Rachel Lynn Delost, DO 2223 Niles Cortland Rd Se, Warren, OH 44484-3043 Ph: (330) 965-8760 |
News Archive
Ore Pharmaceuticals Inc. ("Ore") announced today the receipt of a written notice from the Nasdaq Stock Market ("Nasdaq") stating that for the previous 30 consecutive business days, the bid price of Ore's listed securities had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market pursuant to Marketplace Rule 5550(a)(2).
A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.
Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago, IL.
In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.
› Verified 6 days ago
Dr. Indira Krishnarao, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 735 Niles Cortland Rd Se, Warren, OH 44484 Phone: 330-856-6365 Fax: 330-609-5088 | |
Kyle L Wagamon, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2660 E Market St, Warren, OH 44483 Phone: 330-393-4000 Fax: 330-392-5870 | |
Morgan Hott, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 735 Niles Cortland Rd Se, Warren, OH 44484 Phone: 330-856-6365 Fax: 330-474-3981 |